Cowen and Company’s Filana Therapeutics FLNA Stock Holding History

Cowen and Company’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-500,000	Closed	-$11.3M	–	710
2023 Q4	$11.3M	Buy	+500,000	New	+$10.6M	0.74%	26
2022 Q4	–	Sell	-19,467	Closed	-$187K	–	722
2022 Q3	$187K	Buy	+19,467	New	+$526K	0.02%	186
2022 Q1	–	Sell	-12,700	Closed	-$555K	–	715
2021 Q4	$555K	Sell	12,700 -162,300	-93%	-$8.51M	0.05%	210
2021 Q3	$10.9M	Buy	+175,000	New	+$14.6M	0.51%	30

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Cowen and Company's FLNA Position: Q1 2024 in Review

Cowen and Company sold out of Filana Therapeutics (FLNA) in Q1 2024, closing a stake of 500,000 shares — an estimated $11.3M sold.

Cowen and Company first reported a position in FLNA in Q3 2021 and held it in 4 quarters. The position peaked at $11.3M in Q4 2023. 143 funds tracked by Wall St. Rank hold FLNA as of Q1 2024.

Cowen and Company reported no remaining Filana Therapeutics position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 500,000 Filana Therapeutics shares in Q1 2024, an estimated $11.3M.
Cowen and Company first reported a position in Filana Therapeutics in Q3 2021 and held it in 4 quarters.
Cowen and Company's Filana Therapeutics position peaked at $11.3M in Q4 2023.
143 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.